Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Anthem Biosciences IPO
Price Band
₹540.0–570.0
Issue Size
₹3395.0 Cr
Lot Size
26 shares
Min Investment
₹14,820
GMP
+₹179.0 (31.4%)
Issue Price
₹570.0
Subject to Sauda
₹3500
Paid only if allotted
Anthem Biosciences IPO AI Summary
- Anthem Biosciences IPO is listed on BSE, NSE in the Biotechnology sector.
- Price band: ₹540.0–₹570.0 per share, lot size 26 shares (min. investment ₹14,820).
- Subscription window: 14 Jul–16 Jul 2025, listing on 21 Jul 2025.
- Current GMP is +₹179.0 (31.4%), an estimated listing price of ₹749 — unofficial and can change daily.
Anthem Biosciences Limited is a biotechnology firm focused on CRDMO services, showcasing strong revenue growth and a robust business model. With an IPO priced at ₹570, the company is positioned to expand its operations and enhance its market presence.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Anthem Biosciences IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 16 Jul 2025 — not a current signal.
12 of 15 reviewers say Positive
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Anthem Biosciences IPO Grey Market Premium (GMP) Today
GMP
+₹179.0
GMP %
+31.4%
Est. Listing
₹749.0
Updated: 25 Jul 2026 14:14
About the Company
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes. The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale. The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery. As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules). As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan. As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies. As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues. As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers. Competitive Strength One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO. Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices. Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing. Long-standing relationships with a large, diversified and loyal customer base. Professional and experienced leadership team supported by a qualified scientific talent pool.
Company Financials (₹ Cr)
As of 2025-03-31
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Total Income | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| NET Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
Key Ratios
EPS
₹8.07
NAV
₹43.10
ROE
20.82%
ROCE
26.88%
RoNW
20.82%
P/B Value
13.23
P/E Ratio
70.62
Market Cap
₹31867.39 Cr
PAT Margin
23.38%
Debt/Equity
0.05
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| DIVI'S LABORATORIES Limited | 564.87 | 15.35% | 83.22 | 82.53 | 82.53 |
| Cohance Lifesciences Limited | 72.31 | 13.61% | 97.29 | 10.52 | 10.45 |
| Sai Life Sciences Limited | 102.12 | 10.96% | 92.18 | 8.83 | 8.61 |
| Syngene International Ltd | 117.42 | 11.05% | 51.54 | 12.35 | 12.34 |
| Anthem Biosciences Limited This IPO | 43.1 | 20.82% | — | 8.07 | 8.07 |
Promoters
Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹1,133.99 Cr for the period ending 31 Mar 2023, increasing to ₹1,483.07 Cr by 31 Mar 2024, and further rising to ₹1,930.29 Cr by 31 Mar 2025. This indicates a consistent growth trend in revenue over the periods analyzed.
Profit Trend
Profit After Tax was ₹385.19 Cr for the period ending 31 Mar 2023, which increased to ₹367.31 Cr by 31 Mar 2024, and then rose to ₹451.26 Cr by 31 Mar 2025. Although there was a slight dip in profit from 31 Mar 2023 to 31 Mar 2024, the profit rebounded and grew by the end of the next period.
Valuation
At the issue price of ₹570.0, Anthem Biosciences has an implied P/E ratio of approximately 70.62, compared to peers trading at a P/E range of 51.54 to 97.29.
Grey Market Premium, Explained
The grey market refers to the unofficial trading of shares before they are listed on the stock exchange. The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on demand in this unofficial market. A high GMP suggests positive sentiment among investors.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and market conditions. It's important to consider the company's growth potential and the overall sector performance.
Who May Want to Wait
Investors who prefer low-risk investments or those averse to the inherent uncertainties of the biotechnology sector may want to avoid this IPO.
IPO Timeline, Explained
The IPO process includes several key dates: the opening date for subscriptions is July 14, 2025, and the closing date is July 16, 2025. Allotment of shares will occur on July 17, 2025, followed by the listing of shares on July 21, 2025.
Listing Gains — The Risk
While many investors hope to make quick profits on the listing day, these gains are not guaranteed. Market conditions, investor sentiment, and the company's performance can all impact the share price on the first day of trading.
This evaluation is generated from Anthem Biosciences's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Anthem Biosciences IPO GMP today?
Anthem Biosciences IPO GMP today is +₹179.0 (31.4%), indicating an estimated listing price of ₹749. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Anthem Biosciences IPO?
The price band of Anthem Biosciences IPO is ₹540.0–₹570.0 per share.
When does Anthem Biosciences IPO open and close?
Anthem Biosciences IPO opens on 14 July 2025 and closes on 16 July 2025.
When does Anthem Biosciences IPO list on the stock exchange?
Anthem Biosciences IPO listed on 21 July 2025 at ₹749.0.
What is the lot size for Anthem Biosciences IPO?
The lot size for Anthem Biosciences IPO is 26 shares, requiring a minimum investment of ₹14,820.
What is the lot size for this IPO?
The lot size for Anthem Biosciences IPO is 26 shares.
What is the minimum investment required?
The minimum investment required is ₹14,820.
What is the price band for the IPO?
The price band for the IPO is ₹540.0 to ₹570.0.
When is the listing date for the shares?
The listing date for the shares is July 21, 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of an IPO based on demand in the unofficial market.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
14 Jul 2025
Close
16 Jul 2025
Allotment
17 Jul 2025
Listing
21 Jul 2025
Similar IPOs in Biotechnology
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Anthem Biosciences?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.